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A B S T R A C T
A pooled analysis of data from 13 phase III studies of telithromycin in the treatment of community-
acquired pneumonia, acute exacerbations of chronic bronchitis, acute sinusitis or group A b-haemolytic
streptococcal pharyngitis and tonsillitis was undertaken. Causative key respiratory tract pathogens
(Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus and
Streptococcus pyogenes) were isolated at entry to the studies from cultures of relevant respiratory
samples and tested for their susceptibility to telithromycin, penicillin and macrolides (erythromycin A).
The combined clinical and bacteriological efficacy of telithromycin at the post-therapy, test-of-cure visit
(days 17–24) was assessed in patients from whom a microbiologically evaluable pathogen was isolated
at entry. More than 98% of key respiratory pathogens isolated, including penicillin G- and macrolide
(erythromycin A)-resistant strains of S. pneumoniae, demonstrated full or intermediate susceptibility to
telithromycin in vitro at the breakpoints of £ 1.0 mg ⁄L (susceptible) and 2.0 mg ⁄L (intermediate) used
for the purpose of evaluating the susceptibility of isolates recovered during the clinical trials. Treatment
with telithromycin 800 mg once-daily for 5, 7 or 7–10 days resulted in high rates of clinical cure (88.5%)
and a satisfactory bacteriological outcome (88.9%), similar to the figures seen with comparator
antibacterial agents. Clinical cure and eradication rates were good for all key respiratory pathogens,
including penicillin G- and macrolide (erythromycin A)-resistant S. pneumoniae. The results suggest that
telithromycin will provide effective empirical therapy for community-acquired upper and lower
respiratory tract infections.
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I N T R O D U C T I O N
Community-acquired respiratory tract infections
(RTIs), namely community-acquired pneumonia
(CAP), acute exacerbations of chronic bronchitis
(AECB), acute sinusitis, and pharyngitis and
tonsillitis, account for considerable morbidity
and can result in serious complications, including
death, if left untreated [1–4]. Successful manage-
ment of patients with community-acquired RTIs
therefore dictates the prompt use of empirical
therapy with an antibacterial that provides good
coverage of all key respiratory pathogens likely to
be encountered. However, a global pattern of
decreasing susceptibility and ⁄ or increasing emer-
gence of resistance has become apparent in recent
years, and this is starting to have an impact on the
choice of antibacterial agent. For example, key
respiratory pathogens such as Streptococcus pneu-
moniae are becoming resistant to b-lactams and ⁄ or
macrolides [5,6], while macrolide resistance
among Streptococcus pyogenes is increasing in
many countries [7–10]. Such resistance threatens
the clinical usefulness of many of the currently
used antibacterial agents in the treatment of
community-acquired RTIs [11–14], and highlights
the need for additional agents that retain activity
against resistant pathogens, and which also have
a low potential to induce—or select for—resistant
strains.
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Telithromycin is the first of a new class of
antibacterial agents—the ketolides—developed
specifically for the treatment of community-
acquired upper and lower RTIs [15], including
those caused by pathogens resistant to commonly
used antibiotics. Numerous in-vitro studies have
shown that telithromycin has excellent activity
against common respiratory pathogens such as
S. pneumoniae, including isolates that are resistant
to penicillin G and ⁄ or macrolides (erythromycin
A) S. pyogenes and Moraxella catarrhalis, and good
activity against Haemophilus influenzae [16–26].
Moreover, telithromycin is active against atypical
and intracellular respiratory pathogens such as
Mycoplasma pneumoniae, Chlamydophila (Chlamy-
dia) pneumoniae and Legionella pneumophila [27–30],
which are being identified with increasing
frequency in patients with CAP [31] as a result
of improved diagnostic techniques. The well-
balanced antibacterial spectrum of telithromycin
is accompanied by a low potential to induce—or
select for—resistance [32,33], a profile that high-
lights the potential utility of this new agent for the
treatment of community-acquired RTIs.
The efficacy and safety of telithromycin, at an
oral dose of 800 mg once-daily, have been con-
firmed in 13 phase III clinical trials in patients
with community-acquired upper and lower RTIs,
most of which included the current antibacterial
‘standard of care’ as comparator [15,34–43]. The
present paper provides a pooled analysis of these
studies in terms of the clinical and bacteriological
efficacy of telithromycin, with a particular focus
on activity against key respiratory tract patho-
gens.
M A T E R I A L S A N D M E T H O D S
Patients and study design
The study population comprised adult patients (aged
‡ 18 years) with a confirmed diagnosis of CAP, AECB, acute
sinusitis, or group A b-haemolytic streptococcal pharyngitis ⁄
tonsillitis, who took part in one of 13 multicentre phase III
studies (Table 1). Adolescents (aged 13–18 years) were also
included in the pharyngitis and tonsillitis studies.
The CAP studies included patients with a diagnosis based
on X-ray findings and the presence of at least two of the
following clinical signs and symptoms: cough, production of
purulent sputum, Gram-stain findings consistent with a respir-
atory pathogen, auscultatory findings, dyspnoea or tachyp-
noea, fever, and elevated total peripheral white blood cell
count. The AECB studies included patients with a documented
history of chronic bronchitis who presented with an episode of
Table 1. Summary of the 13 phase III clinical trials with telithromycin included in the pooled analysis
Indication
No. of trials
(study no.) Telithromycin dosage (n) Comparator dosage (n) Reference
CAP 1 (3001) 800 mg once-daily for 10 days (199) AMX 1000 mg three times
daily for 10 days (205)
37
1 (3006) 800 mg once-daily for 10 days (204) CLA 500 mg twice-daily for
10 days (212)
40
1 (3009) 800 mg once-daily for 7–10 days (100) TVA 200 mg once-daily
for 7–10 days (104)
15
2 (3000; 3009OL) 800 mg once-daily for 7–10 days (452) – 36,43
1 (3010) 800 mg once-daily for 7 days (418) – 41
AECB 1 (3003) 800 mg once-daily for 5 days (160) AUG 500 ⁄ 125 mg three times
daily for 10 days (160)
35
1 (3007) 800 mg once-daily for 5 days (182) CXM 500 mg twice-daily for
10 days (191)
15
Acute 1 (3002) 800 mg once-daily for 5 or 10 days (335) – 39
sinusitis 1 (3005) 800 mg once-daily for 5 or 10 days (405) AUG 500 ⁄ 125 mg three times
daily for 10 days (202)
15
1 (3011) 800 mg once-daily for 5 days (240) CXM 250 mg twice-daily
for 10 days (116)
34
Pharyngitis and
tonsillitis
1 (3004) 800 mg once-daily for 5 days (198) PEN 500 mg three times
daily for 10 days (197)
38
1 (3008) 800 mg once-daily for 5 days (232) CLA 250 mg twice-daily
for 10 days (231)
42
AECB, acute exacerbation of chronic bronchitis; CAP, community-acquired pneumonia; AMX, amoxycillin; AUG,
amoxycillin–clavulanate; CLA, clarithromycin; CXM, cefuroxime axetil; PEN, penicillin V (phenoxymethylpenicillin); TVA,
trovafloxacin; n ¼ number of patients (modified intent-to-treat population).
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AECB presumed to be caused by bacterial infection. Clinical
diagnosis of AECB was based on the presence of at least two of
the following signs and symptoms: increased sputum volume,
increased sputum purulence, and increased cough or dys-
pnoea. For the acute sinusitis studies, inclusion criteria inclu-
ded clinical symptoms of acute sinusitis of < 28 days’ duration
and radiological evidence of total sinus opacity and ⁄or air–
fluid levels. Patients with clinical signs and symptoms of acute
pharyngitis and tonsillitis were eligible for inclusion if they had
either a positive streptococcal antigen test from a throat swab or
a positive throat culture for group A b-haemolytic streptococ-
cus. Written informed consent was obtained from all patients or
their parents ⁄ guardians before any study-related procedures.
Human experimentation guidelines of each participating study
centre were followed in the conduct of clinical research.
Study treatments
Eligible patients received oral telithromycin 800 mg once daily
for 7 or 7–10 days (CAP), 5 or 10 days (acute sinusitis), or
5 days (AECB, pharyngitis and tonsillitis) (Table 1). Various
oral antibacterials were included as comparators, depending on
the indication. In the CAP studies, the comparators were
amoxycillin 1000 mg three times daily, clarithromycin 500 mg
twice-daily, and trovafloxacin 200 mg once-daily. Amoxycil-
lin–clavulanate 500 + 125 mg three times daily, and cefuroxi-
me axetil 500 mg twice-daily, were chosen as comparators in
the AECB studies. In the acute sinusitis studies, the compara-
tors were amoxycillin–clavulanate 500 + 125 mg three times
daily, and cefuroxime axetil 250 mg twice-daily. Finally,
comparator antibacterials in the pharyngitis and tonsillitis
studies were penicillin V (phenoxymethylpenicillin) 500 mg
three times daily, and clarithromycin 250 mg twice-daily. All
comparator antibacterials were given as a 10-day course, with
the exception of trovafloxacin, which was given as a 7–10-day
course. Compliance was assessed by unused tablet counts at
the on-therapy and post-therapy visits.
Susceptibility testing
Causative key respiratory tract pathogens (S. pneumoniae,
H. influenzae, M. catarrhalis, Staphylococcus aureus and S. pyo-
genes) were isolated at entry to the study from cultures of
relevant respiratory samples, namely sputum (CAP and AECB
studies), sinus aspirates obtained by sinus puncture or endo-
scopy (acute sinusitis studies) or throat swabs (pharyngitis and
tonsillitis studies, in which swabs were tested for streptococcal
antigen before bacteriological culture was performed), or from
blood (CAP). All isolated bacterial pathogens were categorised
by the investigator as either causative, contaminant, colonising
or part of the normal oral flora (mixed flora). A bacterial
pathogen was considered to be causative if the isolate(s)
obtained at the initial visit was from an appropriate sample (as
defined above) and was identified as an organism that is
generally accepted as pathogenic for the indication under
study. Susceptibility testing of clinical isolates was performed
using disk diffusion methods at each investigator’s local
laboratory. Subcultures of primary isolates were subsequently
retested at a central laboratory (Clinical Microbiology Institute,
Wilsonville, OR, USA, or GR Micro Ltd, London, UK) by disk
diffusion and for MICs by National Committee for Clinical
Laboratory Standards methodology [44]. Susceptibility to
telithromycin was assessed according to the following MIC
breakpoints (susceptible, intermediate and resistant, respect-
ively) as used for the purpose of evaluating isolates recovered
during the clinical trials: streptococci and staphylococci, £ 1.0,
2.0 and ‡ 4.0 mg ⁄L; Haemophilus spp., £ 2.0, 4.0 and ‡ 8.0 mg ⁄L.
PCR analysis for the presence of erm and mef sequences was
performed on isolates of S. pneumoniae and S. pyogenes resistant
to macrolides (erythromycin A) [45].
Assessment of clinical and bacteriological
outcome
The primary outcome was the combined clinical and bacterio-
logical efficacy at the post-therapy, test-of-cure visit, i.e., days
17–24 for CAP, AECB and acute sinusitis studies, and days
16–23 for the pharyngitis and tonsillitis studies. Clinical cure
was defined as clinical improvement or return to the prein-
fection state, while bacteriological outcome was classed as
satisfactory if there was eradication or presumed eradication of
the causative pathogen. Analyses were performed for the bac-
teriologically evaluable, modified intent-to-treat population,
i.e., all patients who had a confirmed diagnosis of the studied
indication and received at least one dose of study medication,
with a pre-therapy bacteriological sample containing at least
one causative pathogen. Those without major protocol viola-
tions were included in the bacteriological per-protocol (PP)
population for analysis of bacteriological outcome. All analy-
ses were completed descriptively.
R E S U L T S
The pooled phase III population comprised 3125
patients treated with telithromycin. Key demo-
graphic characteristics, across indications, are
shown in Table 2.
Table 2. Key demographic characteristics of telithromycin-treated patients across indications (modified intent-to-treat
population)
CAP AECB Acute sinusitis Pharyngitis and tonsillitis
Total no. of patients 1373 342 980 430
Sex, male ⁄ female 779 ⁄ 594 178 ⁄ 164 442 ⁄ 538 171 ⁄ 259
Mean age (years) 44.6 56.3 39.6 31.6
Patients aged ‡ 65 years (%) 196 (14.3) 114 (33.3) 48 (4.9) 2 (0.5)
AECB, acute exacerbation of chronic bronchitis; CAP, community-acquired pneumonia; n ¼ number of patients.
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In-vitro susceptibility
In total, 1894 causative pathogens isolated from
respiratory samples and blood cultures at baseline
were tested for susceptibility to telithromycin.
With application of susceptibility breakpoints as
defined in the clinical trials, > 88% of all patho-
gens were of full or intermediate susceptibility,
with 81.4% of all isolates demonstrating full
susceptibility to telithromycin. Most isolates that
were not susceptible to telithromycin were not key
causative pathogens of community-acquired RTIs
(H. parainfluenzae, Klebsiella pneumoniae, Escherichia
coli and Pseudomonas aeruginosa).
The causative pathogens most frequently isola-
ted from respiratory or blood samples were
S. pneumoniae, H. influenzae, M. catarrhalis,
S. pyogenes and Staph. aureus (Table 3). Overall,
> 98% of these key respiratory pathogens were
either susceptible or of intermediate susceptibility
to telithromycin when breakpoints used for the
purpose of evaluating the susceptibility of isolates
recovered during the clinical trials were applied.
All isolates of S. pneumoniae, including those
resistant to penicillin G or the macrolides (eryth-
romycin A), were of full or intermediate suscep-
tibility (Table 4). Two S. pneumoniae isolates of
intermediate susceptibility to telithromycin were
also resistant to penicillin G and erythromycin A.
In total, 590 (99.3%) of 594 isolates of S. pyogenes
were fully susceptible to telithromycin; the four
isolates that were resistant were all ermB positive.
Eighty-seven of 89 Staph. aureus isolates were
fully susceptible to telithromycin; the two isolates
that were resistant to telithromycin were also
cross-resistant to erythromycin A. All isolates of
M. catarrhalis were inhibited by telithromycin
£ 1 mg/L. Most (239 (69.9%) of 342) H. influenzae
isolates were also susceptible to telithromycin
£ 2 mg ⁄L, while a further 88 (25.7%) H. influenzae
isolates were inhibited by telithromycin £ 4 mg ⁄L
(95.6% in total).
Of 69 pathogens isolated from blood cultures
in patients with CAP, 68 (98.6%) were fully
susceptible to telithromycin. These comprised
61 isolates of S. pneumoniae, including penicillin
G- and macrolide (erythromycin A)-resistant
strains, one isolate of Staph. aureus, two isolates
of viridans group streptococci, two isolates of
Staph. haemolyticus, one isolate of Staph. hyicus,
and one isolate of Bacillus cereus. (Note: viridans
group streptococci, Staph. haemolyticus, Staph.
hyicus and Bacillus cereus, although not generally
considered to be causative of community-
acquired RTIs, were assessed by the investigators
as causative pathogens. These are most often
interpreted as skin contaminants when recovered
from blood cultures.) Only one organism isolated
from blood—E. coli—was resistant to telithromy-
cin (as expected, based on the antibacterial spec-
trum of this agent).
Clinical and bacteriological efficacy
Combined clinical cure rates and bacteriological
outcome at the post-therapy, test-of-cure visit for
telithromycin and comparator modified intent-
to-treat populations are summarised in Table 5.
Table 3. Causative pathogens isolated at entry from res-
piratory ⁄blood cultures from patients with community-
acquired respiratory tract infections
Pathogen
Number (%)
of isolates
Community-acquired pneumonia
Streptococcus pneumoniae 250 (33.7)
Haemophilus influenzae 197 (26.6)
Moraxella catarrhalis 45 (6.1)
Staphylococcus aureus 39 (5.3)
Klebsiella pneumoniae 23 (3.1)
Othera 187 (25.2)
Total no. of isolates 741
Acute exacerbations of chronic bronchitis
Haemophilus influenzae 59 (39.6)
Streptococcus pneumoniae 28 (18.8)
Moraxella catarrhalis 29 (19.5)
Staphylococcus aureus 5 (3.4)
Klebsiella pneumoniae 2 (1.3)
Otherb 26 (17.4)
Total no. of isolates 149
Acute maxillary sinusitis
Streptococcus pneumoniae 116 (27.6)
Haemophilus influenzae 88 (21.0)
Staphylococcus aureus 45 (10.7)
Moraxella catarrhalis 30 (7.1)
Klebsiella pneumoniae 3 (0.7)
Streptococcus pyogenes 2 (0.5)
Otherc 136 (32.4)
Total no. of isolates 420
Pharyngitis and tonsillitis
Streptococcus pyogenes 594 (100)
Total no. of isolates 594
aIncluding Haemophilus parainfluenzae, Escherichia coli,
Klebsiella pneumoniae and Pseudomonas aeruginosa.
bIncluding H. parainfluenzae, E. coli and Pseudomonas spp.
cIncluding H. parainfluenzae, group C and G b-haemolytic
streptococci, coagulase-negative staphylococci, Bacteroides
spp., E. coli and P. aeruginosa.
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Treatment with telithromycin for 5 or 7–10 days
resulted in high rates of clinical cure and satis-
factory bacteriological outcome that were similar
to those seen with the comparator antibacterial
agents. Overall, 88.5% of telithromycin-treated
patients were clinically cured and 88.9% of
causative pathogens were eradicated or presumed
to be eradicated. For the comparator agents, the
rates of clinical cure in the various conditions
ranged from 76.3% (for amoxycillin–clavulanate
with acute sinusitis and AECB combined) to
92.1% (for penicillin V with tonsillitis and phar-
yngitis), while eradication rates ranged from
80.0% (amoxycillin–clavulanate and cefuroxime
axetil) to 95.6% (trovafloxacin).
For telithromycin-treated patients, the PP clin-
ical cure and bacteriological eradication rates at
the post-therapy, test-of-cure visit for key causa-
tive pathogens, according to telithromycin sus-
ceptibility, are shown in Table 6. Overall, clinical
cure and eradication rates were good for all
key respiratory pathogens, including penicillin
G- and macrolide (erythromycin A)-resistant
S. pneumoniae. Clinical efficacy in infections
caused by erythromycin A-resistant S. pneumoniae
was comparable with that observed for all S. pneu-
Table 4. Susceptibilitya to telithro-
mycin of key respiratory pathogens
isolated from respiratory or blood
samples
Pathogen
No. of
isolates
Susceptible
n (%)
Intermediate
n (%)
Resistant
n (%)
Total key pathogens 1523 1412 (92.7) 90 (5.9) 21 (1.4)
Streptococcus pneumoniae
All isolates 394 392 (99.5) 2 (0.5) –
Penicillin G resistantb 47 45 (95.7) 2 (4.3)d –
Erythromycin A resistantc 58 56 (96.6) 2 (3.4)d –
Haemophilus influenzae
All isolates 342 239 (69.9) 88 (25.7) 15 (4.4)
b-Lactamase positive 63 49 (77.8) 13 (20.6) 1 (1.6)
Staphylococcus aureus 89 87 (97.8) – 2 (2.2)
Streptococcus pyogenes 594 590 (99.3) – 4 (0.7)
aBreakpoints as defined in the clinical study protocols (susceptible, intermediate
and resistant) were adopted as follows: streptococci and staphylococci,
£ 1.0 mg ⁄L, 2.0 mg ⁄L and ‡ 4.0 mg ⁄L; Haemophilus influenzae, £ 2.0 mg ⁄L,
4.0 mg ⁄L and ‡ 8.0 mg ⁄L; no breakpoints were available for Moraxella catarrhalis,
but all isolates were inhibited by £ 1 mg/L.
bMIC ‡ 2.0 mg ⁄L.
cMIC ‡ 1.0 mg ⁄L.
dIsolates were both penicillin and erythromycin resistant.
Table 5. Rates of clinical cure and
satisfactory bacteriological outcome
at the post-therapy, test-of-cure visit
(bacteriologically evaluable modi-
fied intent-to-treat population)
Antibacterial
Clinical cure,
n ⁄N (%)a
Satisfactory bacteriological
outcome, n ⁄N (%)b
Telithromycin 1282 ⁄ 1448 (88.5) 1265 ⁄ 1423 (88.9)
5-day coursec,d 584 ⁄ 670 (87.2) 566 ⁄ 648 (87.3)
7–10-day coursec,e 698 ⁄ 778 (89.7) 699 ⁄ 775 (90.2)
Clarithromycine 186 ⁄ 205 (90.7) 175 ⁄ 195 (89.7)
Trovafloxacine 39 ⁄ 44 (88.6) 43 ⁄ 45 (95.6)
Amoxycilline 53 ⁄ 62 (85.5) 52 ⁄ 61 (85.2)
Cefuroxime axetilc,d 83 ⁄ 105 (79.0) 84 ⁄ 105 (80.0)
Amoxycillin–clavulanatec,d 45 ⁄ 59 (76.3) 44 ⁄ 55 (80.0)
Penicillin Vf 129 ⁄ 140 (92.1) 119 ⁄ 135 (88.1)
aClinical improvement or return to preinfection state.
bDocumented or presumed eradication of the pathogen from respiratory
secretions and ⁄ or blood cultures.
cAcute sinusitis.
dAcute exacerbations of chronic bronchitis.
eCommunity-acquired pneumonia.
fTonsillitis ⁄pharyngitis.
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moniae infections. For infections caused by H. influ-
enzae, rates of satisfactory clinical outcome were
slightly lower (6 ⁄ 8) among strains with telithro-
mycin MICs ‡ 8 mg ⁄L.
Among patients in the PP population with
pneumococcal bacteraemia, clinical cure and
eradication rates were both 91.5% (43 ⁄ 47) for
telithromycin. Those infected with penicillin
G- and ⁄ or macrolide (erythromycin A)-resistant
strains both achieved clinical cure and eradication
rates of 7 ⁄ 9 (77.8%). The four cases with pneu-
mococcal bacteraemia which were assessed as
clinical failures at the post-therapy, test-of-cure
visit included two patients switched to another
antibiotic before blood cultures were repeated
and one patient from whom penicillin G- and
erythromycin A-resistant S. pneumoniae was erad-
icated (the case was deemed to be a clinical failure
because of treatment with another antibiotic for
urinary Staph. aureus infection). The remaining
patient demonstrated persistence of infection with
a penicillin G- and erythromycin A-resistant
S. pneumoniae strain that was susceptible to
telithromycin (MIC 0.12 mg ⁄L). Thus, only one
of the four pneumococcal bacteraemia clinical
failures (all of which were resolved with subse-
quent antibacterial therapy) was a documented
microbiological treatment failure.
Ten patients in the PP population treated with
telithromycin had bacteraemia caused by organ-
isms other than S. pneumoniae (one B. cereus, one
Staph. hyicus, two Staph. haemolyticus, one Strepto-
coccus milleri, one Staphylococcus spp. and four
viridans group streptococci). All of these patients
achieved clinical cure with presumed bacterial
eradication.
D I S C U S S I O N
Telithromycin is the first ketolide antibacterial
agent to be approved for clinical use. The keto-
lides constitute a novel class within the
macrolide–lincosamide–streptograminB group of
antibacterial agents. Telithromycin was specific-
ally designed to provide optimal empirical ther-
apy for community-acquired upper and lower
RTIs. Its spectrum of antibacterial activity covers
all relevant common respiratory pathogens, inclu-
ding isolates resistant to other antibacterials, and
atypical or intracellular pathogens [46]. Com-
pared with many antibacterial agents currently
recommended for the treatment of such infec-
tions, telithromycin demonstrates high rates of
clinical and bacteriological efficacy [15]. This was
demonstrated in 13 phase III clinical trials, the
results of which were pooled for the purpose of
the present study.
As this was a pooled analysis of data from a
number of open-label and comparator-controlled
Table 6. Clinical cure and eradication rates in telithromy-
cin-treated patients, by key causative pathogen and
according to telithromycin MICa, at the post-therapy,
test-of-cure visit (bacteriologically evaluable per-protocol
population)
Pathogen and
telithromycin MIC
No. of
isolates
Clinical
cure (%)
Eradication
(%)
Streptococcus pneumoniae
All isolates 245 93.1 94.3
MIC £ 1.0 mg ⁄L 244 93.0 94.3
MIC 2.0 mg ⁄L 1 100 100
MIC ‡ 4.0 mg ⁄L 0 – –
Streptococcus pneumoniae (PEN-R)
All isolates 29 82.8 82.8
MIC £ 1.0 mg ⁄L 28 82.1 82.1
MIC 2.0 mg ⁄L 1b 100 100
MIC ‡ 4.0 mg ⁄L 0 – –
Streptococcus pneumoniae (ERY-R)
All isolates 37 83.8 83.8
MIC £ 1.0 mg ⁄L 36 83.3 83.3
MIC 2.0 mg ⁄L 1b 100 100
MIC ‡ 4.0 mg ⁄L 0 – –
Haemophilus influenzae
All isolates 178 87.1 84.3
MIC £ 2.0 mg ⁄L 129 85.3 82.2
MIC 4.0 mg ⁄L 41 95.1 92.7
MIC ‡ 8.0 mg ⁄L 8 75.0 75.0
Moraxella catarrhalis
All isolates 51 92.2 94.1
Staphylococcus aureus
All isolates 39 87.2 89.7
MIC £ 1.0 mg ⁄L 39 87.2 89.7
MIC 2.0 mg ⁄L 0 – –
MIC ‡ 4.0 mg ⁄L 0 – –
Streptococcus pyogenes
All isolates 249c 93.2 88.4
MIC £ 1.0 mg ⁄L 247 93.1 88.3
MIC 2.0 mg ⁄L 0 – –
MIC ‡ 4.0 mg ⁄L 0 – –
Streptococcus pyogenes (ERY-R)
All isolates 11 90.9 27.3
MIC £ 1.0 mg ⁄L 11 90.9 27.3
MIC 2.0 mg ⁄L 0 – –
MIC ‡ 4.0 mg ⁄L 0 – –
aBreakpoints as defined in the clinical study protocols.
bIsolate was both penicillin G and erythromycin A resist-
ant.
cMICs were not determined for two isolates.
ERY-R, erythromycin A resistant (MIC ‡ 1.0 mg ⁄L); PEN-
R, penicillin G resistant (MIC ‡ 2.0 mg ⁄L).
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clinical trials across four different indications, a
formal statistical comparison of these data was
not possible. However, a descriptive analytical
approach was adopted to compare the pooled
activity of telithromycin with that of comparators.
Overall, our findings confirm high levels of
susceptibility to telithromycin among all patho-
gens most commonly associated with community-
acquired RTIs, supporting the potential utility of
telithromycin as appropriate empirical therapy
for RTI indications.
In total, 99.5% of S. pneumoniae isolates were
susceptible to £ 1.0 mg ⁄L telithromycin, and all
were susceptible to £ 2.0 mg ⁄L telithromycin,
including penicillin G- and macrolide (erythro-
mycin A)-resistant strains. This is an important
finding, given the increasing prevalence of such
resistance among pneumococci [5,6]. Telithromy-
cin also provided good coverage against other
major respiratory pathogens, including M. catar-
rhalis and S. pyogenes. High rates of clinical cure
and bacteriological eradication (87.1% and 84.3%,
respectively) were achieved among H. influenzae
isolates, even for those isolates that had a telith-
romycin MIC as high as 4.0 mg ⁄L (95.1% and
92.7%, respectively). While it must be accepted
that the number of isolates for which the telith-
romycin MIC equalled 4.0 mg ⁄L was relatively
small (n ¼ 41), the apparent success of telithro-
mycin against strains of H. influenzae with inter-
mediate susceptibility may be explained in part
by pharmacokinetic and pharmacodynamic para-
meters. Telithromycin demonstrates concentra-
tion-dependent bactericidal activity against key
respiratory pathogens, including S. pneumoniae,
M. catarrhalis and H. influenzae [47,48]. Further-
more, Drusano et al. [49] found that CAP patients,
from whom organisms with telithromycin MICs
as high as 4 mg ⁄L (including H. influenzae) were
isolated, had a high probability of success with
telithromycin treatment. In the present study,
clinical cure and eradication rates for telithromy-
cin were slightly lower for strains of H. influenzae
with MICs ‡ 8 mg ⁄L, although the number of
such isolates was very small (n ¼ 8). Azithromy-
cin, which has similar pharmacokinetic and phar-
macodynamic properties to telithromycin, has
breakpoints of £ 4, 8 and ‡ 16 mg ⁄L, respectively,
for susceptible, intermediate and resistant isolates
of H. influenzae. Based on these data and new data
from clinical trials conducted since the original
phase III studies, breakpoints of £ 4, 8 and
‡ 16 mg ⁄L for telithromycin against H. influenzae
have been approved by the subcommittee of the
National Committee for Clinical Laboratory
Standards (Aventis Pharmaceuticals, personal
communication). Applying a susceptibility break-
point of £ 4 mg ⁄L to the isolates of H. influenzae
from respiratory or blood samples in this study
would result in 95.6% (327 ⁄ 342) of isolates being
classified as susceptible to telithromycin (see
Table 4). Overall, the results therefore suggest
that empirical therapy with telithromycin may
well achieve clinical and bacteriological success
for those infections caused by H. influenzae,
although further clinical experience with this
agent is required to confirm this conclusion.
It is well established that bacteraemia is a
serious complication of community-acquired
RTIs such as CAP and AECB. Thus, for pneumo-
coccal pneumonia, bacteraemia occurs in up to
30% of patients and increases the risk of mortal-
ity by up to 5.2-fold [50]. In the present study,
47 patients with pneumococcal bacteraemia were
identified in the PP population, including a minor
proportion infected with penicillin G- and macro-
lide (erythromycin A)-resistant strains. Overall,
treatment with telithromycin was associated with
high rates of clinical and bacteriological efficacy
in these at-risk patients (91.5% and 91.5%,
respectively). Telithromycin displays concentra-
tion-dependent killing, and its AUC ⁄MIC ratio
has been shown to be the pharmacodynamic and
pharmacokinetic variable that best predicts out-
come [51]. In addition, pharmacokinetic studies
have demonstrated that, following oral adminis-
tration, telithromycin achieves plasma concentra-
tions adequate to maintain activity against key
respiratory pathogens throughout the dosing
period [52]. These factors may account for its
activity against invasive isolates, and are import-
ant properties for any oral agent intended for
the empirical treatment of community-acquired
RTIs.
The comparator antibacterials used in the phase
III clinical trials of telithromycin were generally
given as a 10-day course of therapy, with some
agents requiring multiple daily administration.
Several studies have demonstrated that such
protracted courses of treatment, and ⁄ or the need
to administer doses throughout the day, may be
associated with reduced compliance, especially
once the symptoms of the infection start to resolve
[53–55]. A reduction in compliance can, in turn,
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result in an increased risk of treatment failure and
may encourage the emergence of drug-resistant
organisms. The rates of clinical cure and satisfac-
tory bacteriological outcome observed in the
present analysis for a 5-day course of telithromy-
cin were comparable to those observed for a
10-day course of this agent and other antibacterial
agents. These results are similar to findings from
an individual study of patients treated with 5- or
10-day courses of telithromycin for acute sinusitis
[39]. A 5-day course of treatment with telithro-
mycin 800 mg once-daily may therefore provide a
short and reliable treatment regimen that poten-
tially increases patients’ adherence to the course
of treatment.
In conclusion, telithromycin 800 mg once-daily
appears to provide excellent coverage against
clinical isolates of key respiratory pathogens,
including those isolated from blood cultures and
those resistant to either penicillin G or the
macrolides (erythromycin A), with high rates of
clinical cure and bacterial eradication. These
results indicate that telithromycin should provide
effective first-line empirical therapy for commu-
nity-acquired upper and lower RTIs.
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